Literature DB >> 15714313

Glycosaminoglycan excretion in children with nephrotic syndrome.

Nurcan Cengiz1, Aysun K Bayazit, Aytul Noyan, Ruksan Anarat, Ali Anarat.   

Abstract

Although most childhood nephrotic syndromes respond to steroid treatment, steroid resistant nephrotic syndrome (SRNS) is also common and is particularly difficult to treat. This study investigated the role of glycosaminoglycans (GAG) in the pathogenesis and clinical course of nephrotic syndrome in children. Thirty-four children (21 males and 13 females, mean age 3.7+/-1.6 years) with steroid-sensitive nephrotic syndrome and 20 children with steroid-resistant nephrotic syndrome (12 males and 8 females, mean age 10.9+/-3.8 years; of the twenty, four had primary SRNS (FSGS) and the others had secondary SRNS) were included the study. Mean urine levels of GAG relative to creatinine (U(GAG)/U(Cr)) in patients with SRNS (n=20, 113.01+/-78.46 mg g(-1) Cr) and in patients experiencing the nephrotic period of steroid-sensitive nephrotic syndrome (n=34, 132.15+/-101.55 mg g(-1) Cr) were both significantly higher than mean U(GAG)/U(Cr) for control subjects (n=30, 51.83+/-47.66 mg g(-1) Cr) (P<0.01 for both). Patients excreted significantly more GAG during the nephrotic period of steroid-sensitive nephrotic syndrome than during remission (132.15+/-101.55 vs 39.11+/-42.73 mg g(-1) Cr, respectively; P<0.01). There was, however, no significant difference between U(GAG)/U(Cr) for patients with steroid-resistant nephrotic syndrome and U(GAG)/U(Cr) in the nephrotic period of steroid-sensitive nephrotic syndrome. Urine GAG excretion correlated significantly with the severity of proteinuria. The results suggest that GAG play a significant role in the pathogenesis of nephrotic syndrome but that GAG excretion is not a marker for response to steroid treatment in pediatric patients with this condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15714313     DOI: 10.1007/s00467-004-1739-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  26 in total

Review 1.  Experimental and clinical pharmacology of glycosaminoglycans (GAGs).

Authors:  G Soldani; J Romagnoli
Journal:  Drugs Exp Clin Res       Date:  1991

Review 2.  The role of dystroglycan, a novel receptor of laminin and agrin, in cell differentiation.

Authors:  K Matsumura; H Yamada; F Saito; Y Sunada; T Shimizu
Journal:  Histol Histopathol       Date:  1997-01       Impact factor: 2.303

3.  A highly cationic protein in plasma and urine of children with steroid-responsive nephrotic syndrome.

Authors:  M Levin; P Gascoine; M W Turner; T M Barratt
Journal:  Kidney Int       Date:  1989-11       Impact factor: 10.612

4.  Urinary excretion of glycosaminoglycans and brush border and lysosomal enzymes as markers of glomerular and tubular involvement in kidney diseases.

Authors:  B Baggio; G Gambaro; G Briani; S Favaro; A Borsatti
Journal:  Contrib Nephrol       Date:  1984       Impact factor: 1.580

5.  Loss of anionic sites from the glomerular basement membrane in aminonucleoside nephrosis.

Authors:  J P Caulfield; M G Farquhar
Journal:  Lab Invest       Date:  1978-11       Impact factor: 5.662

6.  Glomerular charge and urinary protein excretion: effects of systemic and intrarenal polycation infusion in the rat.

Authors:  V M Vehaskari; E R Root; F G Germuth; A M Robson
Journal:  Kidney Int       Date:  1982-08       Impact factor: 10.612

Review 7.  Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane.

Authors:  A J Groffen; J H Veerkamp; L A Monnens; L P van den Heuvel
Journal:  Nephrol Dial Transplant       Date:  1999-09       Impact factor: 5.992

8.  Heparan sulfate--rich anionic sites in the human glomerular basement membrane. Decreased concentration in congenital nephrotic syndrome.

Authors:  R L Vernier; D J Klein; S P Sisson; J D Mahan; T R Oegema; D M Brown
Journal:  N Engl J Med       Date:  1983-10-27       Impact factor: 91.245

9.  Glomerular charge alterations in human minimal change nephropathy.

Authors:  C R Bridges; B D Myers; B M Brenner; W M Deen
Journal:  Kidney Int       Date:  1982-12       Impact factor: 10.612

10.  Glomerular anionic sites in minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Y Kitano; N Yoshikawa; H Nakamura
Journal:  Clin Nephrol       Date:  1993-10       Impact factor: 0.975

View more
  1 in total

1.  Low molecular weight heparin may benefit nephrotic remission in steroid‑sensitive nephrotic syndrome via inhibiting elastase.

Authors:  Songhui Zhai; Lijuan Hu; Lin Zhong; Yuhong Tao; Zheng Wang
Journal:  Mol Med Rep       Date:  2017-10-03       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.